Comparative Pharmacology
Head-to-head clinical analysis: FLUDARABINE PHOSPHATE versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARABINE PHOSPHATE versus OTREXUP PFS.
FLUDARABINE PHOSPHATE vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine phosphate is a purine analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to apoptosis in lymphocytes.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
25 mg/m2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Terminal half-life of 2-fluoro-ara-A is approximately 20 hours (range 10–30 hours). Clinical context: accumulation occurs with repeated dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Renal excretion of the active metabolite 2-fluoro-ara-A accounts for approximately 60% of drug elimination. Biliary/fecal elimination is minimal (<5%).
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Antimetabolite
Antimetabolite